homoharringtonine and Glioma

homoharringtonine has been researched along with Glioma* in 1 studies

Other Studies

1 other study(ies) available for homoharringtonine and Glioma

Article	Year
Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors. Journal of neuro-oncology, 1990, Volume: 9, Issue:2 A phase II trial of Homoharringtonine (HHT) was performed in 15 patients with recurrent or progressive malignant glioma. The drug was administered at a initial dose of 4 mg/m2/day by continuous 5 day intravenous infusion (3 mg/m2/day x 5 days for heavily pretreated patients). Courses were repeated every 3-4 weeks upon recovery from toxicity. No objective antitumor regressions occurred. Two patients had no change in their CT brain scans for 2-3 months and one patient had stable disease for 6 months. Toxicity was tolerable and included myelosuppression and occasionally mild hypotension. Chemosensitivity testing with HHT and several other chemotherapy drugs was performed in glioma cell lines, including cell lines derived from these patients. The results suggest that HHT is an inactive drug in malignant glioma using this dose schedule. Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Drug Evaluation; Female; Glioblastoma; Glioma; Harringtonines; Homoharringtonine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Tumor Cells, Cultured	1990

Article

Year

Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors.

Journal of neuro-oncology, 1990, Volume: 9, Issue:2

A phase II trial of Homoharringtonine (HHT) was performed in 15 patients with recurrent or progressive malignant glioma. The drug was administered at a initial dose of 4 mg/m2/day by continuous 5 day intravenous infusion (3 mg/m2/day x 5 days for heavily pretreated patients). Courses were repeated every 3-4 weeks upon recovery from toxicity. No objective antitumor regressions occurred. Two patients had no change in their CT brain scans for 2-3 months and one patient had stable disease for 6 months. Toxicity was tolerable and included myelosuppression and occasionally mild hypotension. Chemosensitivity testing with HHT and several other chemotherapy drugs was performed in glioma cell lines, including cell lines derived from these patients. The results suggest that HHT is an inactive drug in malignant glioma using this dose schedule.

Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Drug Evaluation; Female; Glioblastoma; Glioma; Harringtonines; Homoharringtonine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Tumor Cells, Cultured

1990